Alpha Teknova, Inc.
HealthcareNASDAQ:TKNO · NASDAQ Global Market
-$0.20 today
Vol 0.15M · Avg 0.13M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$41.8M of revenue converted into -$17.2M of net income for the selected period. Gross margin is 33.4% and net margin is -41.1%, showing how much revenue survives after costs and taxes. EPS is $-0.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M +7.4% | $37.7M +2.9% | $36.7M -11.4% | $41.4M +12.3% | $36.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $27.1M -11.3% | $30.5M +15.6% | $26.4M +10.2% | $23.9M +24.2% | $19.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.4M +85.9% | $7.2M -29.8% | $10.3M -41.1% | $17.5M -0.8% | $17.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 33.2% +14.0pp | 19.2% -8.9pp | 28.1% -14.1pp | 42.2% -5.6pp | 47.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.2M -20.4% | $2.8M -50.4% | $5.6M -28.0% | $7.7M +79.4% | $4.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $27.1M -8.1% | $29.5M -15.3% | $34.8M -7.1% | $37.4M +54.9% | $24.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $30.4M -8.9% | $33.4M -27.2% | $45.9M -31.7% | $67.1M +126.6% | $29.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.3M -3.6% | $6.6M +16.2% | $5.7M +78.8% | $3.2M +9.8% | $2.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$10.1M +48.1% | -$19.6M +23.4% | -$25.5M +0.6% | -$25.7M -180.3% | -$9.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -25.0% +26.8pp | -51.8% +17.8pp | -69.6% -7.6pp | -62.0% -37.2pp | -24.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$17.0M +35.1% | -$26.1M +26.5% | -$35.6M +28.4% | -$49.7M -313.5% | -$12.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -41.9% +27.4pp | -69.3% +27.7pp | -96.9% +22.9pp | -119.9% -87.3pp | -32.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 -100.0% | $213.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $710.0K +3.3% | $687.0K -17.5% | $833.0K | $0 -100.0% | $589.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$225.0K +67.2% | -$687.0K +54.7% | -$1.5M -665.3% | $268.0K +142.6% | -$629.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$17.2M +35.9% | -$26.8M +27.6% | -$37.1M +24.9% | -$49.4M -290.8% | -$12.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -42.5% +28.6pp | -71.1% +30.0pp | -101.1% +18.2pp | -119.2% -85.0pp | -34.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $58.0K +165.9% | -$88.0K +70.5% | -$298.0K +84.5% | -$1.9M +32.1% | -$2.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$17.3M +35.5% | -$26.7M +27.3% | -$36.8M +22.5% | -$47.5M -384.2% | -$9.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -42.6% +28.3pp | -70.9% +29.4pp | -100.3% +14.3pp | -114.6% -88.0pp | -26.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +43.9% | -$1 +50.9% | -$1 +31.4% | -$2 -382.9% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +43.9% | -$1 +50.9% | -$1 +31.4% | -$2 -382.9% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.5M +14.4% | $46.7M +46.9% | $31.8M +13.3% | $28.1M +0.3% | $28.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $53.5M +14.4% | $46.7M +46.9% | $31.8M +13.3% | $28.1M +0.3% | $28.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$679.20M
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
$600.84M
Canopy Growth Corporation
NASDAQ:CGC
$425.84M
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
Exagen Inc.
NASDAQ:XGN
$112.83M
Immutep Limited
NASDAQ:IMMP
$53.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TKNO generate?
Alpha Teknova, Inc. (TKNO) reported $40.52M of revenue in fiscal 2025.
Is TKNO profitable?
Alpha Teknova, Inc. (TKNO) reported -$17,259,000.00 of net income, with a net margin of -42.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.